Monday, 30 April 2018 09:00 AM
MIAMI, FL / ACCESSWIRE / April 30, 2018 / Qrons Inc., (www.Qrons.com) (OTC PINK: QRON) a preclinical biotechnology company that is developing advanced cell-based solutions to combat neurological injuries today announced that it has engaged American Capital Ventures ("ACV"), a boutique provider of comprehensive investor relations services to micro- and small-cap companies, to provide investor relations services to the company.
Jonah Meer, CEO of Qrons Inc, stated, "We are very pleased to announce that we have engaged American Capital Ventures to assist us in strategically presenting our company to the investment community. After interviewing several firms we felt that ACV brings the experience and knowledge we were looking for." Howard Gostfrand, President of American Capital Ventures, commented, "We are equally as pleased to be working with Qrons Inc. on their investor relations program. The Company has secured a license from a prominent Israeli University and is working closely with Dartmouth College on a research study. We look forward to working alongside management in educating their current and new shareholders on these and future initiatives."
About Qrons, Inc.
Headquartered in Miami, Florida, the Company is a publicly traded preclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology could potentially treat a wide range of neurodegenerative diseases. The Company's treatment integrates proprietary, engineered mesenchymal stem cells 3D printable scaffolding, smart materials, and a novel delivery system. The Company entered into a license and research funding agreement ("License Agreement") with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding. The Company is also conducting a research study with Professor Chenfeng Ke of the Chemistry Department at Dartmouth College aiming to develop innovative 3D printable, biocompatible advanced materials and stem cell delivery techniques to treat TBI. The Company is negotiating, a worldwide, royalty‑bearing, exclusive license for Professor Ke's 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.
Safe Harbor Statement
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning our future product development plans, other statements regarding future research, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties, and assumptions that could cause the Company's actual operations, results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development; successful development of clinical studies for any product we may develop, U.S. Food and Drug Administration clearance for any products developed, manufacturing of a commercially-viable version of our system and demonstration of safety and effectiveness sufficient to generate commercial orders by customers for any product we may develop. A more complete description of these risk factors is included in the Company's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Investor Relations Contact:
American Capital Ventures
Howard Gostfrand, President
[email protected]
+1-305.918.7000
SOURCE: Qrons Inc.